<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="iahsp" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">iahsp</book-part-id>
      <title-group>
        <title>
<italic toggle="yes">ALS2</italic>-Related Disorders</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Orrell</surname>
            <given-names>Richard W</given-names>
          </name>
          <degrees>BSc, MD, FRCP</degrees>
          <email>r.orrell@ucl.ac.uk</email>
          <aff>University Department of Clinical Neurosciences<break/>Institute of Neurology<break/>University College London<break/>London, United Kingdom</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2005-10-21" date-type="created">
          <day>21</day>
          <month>10</month>
          <year>2005</year>
        </date>
        <date iso-8601-date="2016-01-28" date-type="updated">
          <day>28</day>
          <month>1</month>
          <year>2016</year>
        </date>
        <date iso-8601-date="2013-04-18" date-type="revised">
          <day>18</day>
          <month>4</month>
          <year>2013</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="alk-nbs" document-type="chapter">
<italic toggle="yes">ALK</italic>-Related Neuroblastic Tumor Susceptibility</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="ano5-md" document-type="chapter">
<italic toggle="yes">ANO5</italic>-Related Muscle Diseases</related-object>
      <abstract id="iahsp.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">ALS2</italic>-related disorders involve retrograde degeneration of the upper motor neurons of the pyramidal tracts and comprise a clinical continuum from infantile ascending hereditary spastic paraplegia (IAHSP), to juvenile forms without lower motor neuron involvement (juvenile primary lateral sclerosis [JPLS]), to forms with lower motor neuron involvement (autosomal recessive juvenile amyotrophic lateral sclerosis [JALS]).</p>
          <list list-type="bullet">
            <list-item>
              <p>IAHSP is characterized by onset of spasticity with increased reflexes and sustained clonus of the lower limbs within the first two years of life, progressive weakness and spasticity of the upper limbs by age seven to eight years, and wheelchair dependence in the second decade with progression toward severe spastic tetraparesis and a pseudobulbar syndrome.</p>
            </list-item>
            <list-item>
              <p>JPLS is characterized by onset and loss of ability to walk during the second year of life, progressive signs of upper motor neuron disease, wheelchair dependence by adolescence, and later loss of motor speech production.</p>
            </list-item>
            <list-item>
              <p>JALS is characterized by onset during childhood (mean age of onset 6.5 years), spasticity of facial muscles, uncontrolled laughter, spastic dysarthria, spastic gait, moderate muscle atrophy (variably present), bladder dysfunction, and sensory disturbances; some individuals are bedridden by age 12 to 50 years.</p>
            </list-item>
          </list>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Results of electrophysiology studies in <italic toggle="yes">ALS2</italic>-related disorders vary by phenotype; MRI shows brain changes in older individuals with IAHSP. Pathogenic variants in <italic toggle="yes">ALS2</italic> have been found in four of 11 families with IAHSP; no other genes/loci are known to be associated with these disorders.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Physical and occupational therapy to promote mobility and independence and use of computer technologies and devices to facilitate writing and voice communication.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Early detection and treatment of hip dislocation and/or spine deformities prevent further complications.</p>
          <p><italic toggle="yes">Surveillance</italic>: Evaluation for feeding difficulties and modification of diet to reduce risk of aspiration.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p><italic toggle="yes">ALS2</italic>-related disorders are inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal diagnosis for pregnancies at increased risk are possible if both pathogenic variants have been identified in an affected family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="iahsp.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="iahsp.Tc" position="anchor" orientation="portrait">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_iahsp.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">ALS2</italic>-Related Disorders: Included Phenotypes <sup>1</sup></th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_iahsp.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Infantile-onset ascending hereditary spastic paralysis</p>
                    </list-item>
                    <list-item>
                      <p>Juvenile primary lateral sclerosis</p>
                    </list-item>
                    <list-item>
                      <p>Autosomal recessive juvenile amyotrophic lateral sclerosis</p>
                    </list-item>
                  </list>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="iahsp.TF.c.1">
              <label>1. </label>
              <p>For other genetic causes of these phenotypes, see <xref ref-type="sec" rid="iahsp.Differential_Diagnosis">Differential Diagnosis</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="iahsp.Diagnosis">
        <title>Diagnosis</title>
        <p><italic toggle="yes">ALS2</italic>-related disorders involve retrograde degeneration of the upper motor neurons of the pyramidal tracts and comprise a clinical continuum that includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Infantile ascending hereditary spastic paraplegia (IAHSP),*</p>
          </list-item>
          <list-item>
            <p>Juvenile forms without lower motor neuron involvement (juvenile primary lateral sclerosis, or JPLS),* and</p>
          </list-item>
          <list-item>
            <p>Forms with lower motor neuron involvement (autosomal recessive juvenile amyotrophic lateral sclerosis, or JALS).</p>
          </list-item>
        </list>
        <p>The different phenotypes reported in the literature are summarized.</p>
        <p>*Note: In some instances, the same entity may be called either juvenile primary lateral sclerosis or IAHSP.</p>
        <sec id="iahsp.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>An <italic toggle="yes">ALS2</italic>-related disorder <bold>should be suspected</bold> in individuals with the following phenotypes, electrophysiologic findings, and neuroimaging findings:</p>
          <sec id="iahsp.Phenotypes">
            <title>Phenotypes</title>
            <p><bold>Infantile-onset ascending hereditary spastic paralysis (IAHSP)</bold> is characterized by the following features [<xref ref-type="bibr" rid="iahsp.REF.lesca.2003.674">Lesca et al 2003</xref>]:</p>
            <list list-type="bullet">
              <list-item>
                <p>Onset of spasticity with increased reflexes and sustained clonus of the lower limbs within the first two years of life</p>
              </list-item>
              <list-item>
                <p>Progressive weakness and spasticity of the upper limbs by age seven to eight years</p>
              </list-item>
              <list-item>
                <p>Wheelchair dependence in the second decade, with progression toward severe spastic tetraparesis and a pseudobulbar syndrome</p>
              </list-item>
              <list-item>
                <p>Preservation of cognitive function</p>
              </list-item>
            </list>
            <p><bold>Juvenile primary lateral sclerosis (JPLS)</bold> is characterized by the following features [<xref ref-type="bibr" rid="iahsp.REF.gascon.1995.313">Gascon et al 1995</xref>, <xref ref-type="bibr" rid="iahsp.REF.yang.2001.160">Yang et al 2001</xref>]:</p>
            <list list-type="bullet">
              <list-item>
                <p>Onset during the second year of life</p>
              </list-item>
              <list-item>
                <p>Loss of ability to walk in the second year of life</p>
              </list-item>
              <list-item>
                <p>Slowly progressive uncomplicated signs of upper motor neuron disease</p>
              </list-item>
              <list-item>
                <p>Wheelchair dependence by adolescence</p>
              </list-item>
              <list-item>
                <p>Later loss of motor speech production</p>
              </list-item>
              <list-item>
                <p>Preservation of cognitive function</p>
              </list-item>
            </list>
            <p><bold>Autosomal recessive juvenile amyotrophic lateral sclerosis (JALS)</bold> (also known as ALS2) is characterized by the following features [<xref ref-type="bibr" rid="iahsp.REF.ben_hamida.1990.347">Ben Hamida et al 1990</xref>]:</p>
            <list list-type="bullet">
              <list-item>
                <p>Onset during childhood (mean age of onset 6.5 years; range 3-20 years)</p>
              </list-item>
              <list-item>
                <p>Spasticity of facial muscles with uncontrolled laughter and spastic dysarthria; spastic gait; in some individuals, mild atrophy of the legs and hands</p>
              </list-item>
              <list-item>
                <p>Variably present moderate muscle atrophy, absence of fasciculations, bladder dysfunction, and sensory disturbances</p>
              </list-item>
              <list-item>
                <p>Some individuals bedridden by age 12 to 50 years (no information is available on age of wheelchair dependence)</p>
              </list-item>
              <list-item>
                <p>Preservation of cognitive function not confirmed</p>
              </list-item>
            </list>
          </sec>
          <sec id="iahsp.Electrophysiologic_Findings">
            <title>Electrophysiologic Findings</title>
            <p><xref ref-type="table" rid="iahsp.T.electrophysiologic_studies_in_al">Table 1</xref> shows the results of various electrophysiologic studies in the different phenotypes of <italic toggle="yes">ALS2</italic>-related disorders.</p>
            <table-wrap id="iahsp.T.electrophysiologic_studies_in_al" position="anchor" orientation="portrait">
              <label>Table 1. </label>
              <caption>
                <p>Electrophysiologic Studies in <italic toggle="yes">ALS2</italic>-Related Disorders by Phenotype</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_1">Study</th>
                    <th id="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2" valign="middle" colspan="3" align="left" scope="colgroup" rowspan="1">Phenotype</th>
                  </tr>
                  <tr>
                    <th headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2" id="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">IAHSP</th>
                    <th headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2" id="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">JPLS</th>
                    <th headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2" id="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">JALS</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <bold>MEP&#x000a0;<sup>1</sup></bold>
                    </td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Severe dysfunction of the corticospinal tracts&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">NA&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">Absent or reduced action potential, suggesting dysfunction of corticospinal tracts&#x000a0;<sup>4</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <bold>SSEP&#x000a0;<sup>5</sup></bold>
                    </td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Normal in early stages; abnormal in later stages</td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Poorly configured; normal central conduction</td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">NA&#x000a0;<sup>3</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <bold>EMG&#x000a0;<sup>6</sup></bold>
                    </td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">No signs of denervation</td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">No signs of denervation</td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">Signs of denervation</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <bold>NCV&#x000a0;<sup>7</sup></bold>
                    </td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <bold>VEP&#x000a0;<sup>8</sup></bold>
                    </td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <bold>BAER&#x000a0;<sup>9</sup></bold>
                    </td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <bold>TCMS&#x000a0;<sup>10</sup></bold>
                    </td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">No motor evoked potentials</td>
                    <td headers="hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_1_2 hd_h_iahsp.T.electrophysiologic_studies_in_al_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="iahsp.TF.1.1">
                  <label>1.&#x000a0;</label>
                  <p>Motor evoked potentials</p>
                </fn>
                <fn id="iahsp.TF.1.2">
                  <label>2.&#x000a0;</label>
                  <p>Primitive, pure degeneration of the upper motor neurons</p>
                </fn>
                <fn id="iahsp.TF.1.3">
                  <label>3.&#x000a0;</label>
                  <p>Not available</p>
                </fn>
                <fn id="iahsp.TF.1.4">
                  <label>4. </label>
                  <p>
                    <xref ref-type="bibr" rid="iahsp.REF.kress.2005.800">Kress et al [2005]</xref>
                  </p>
                </fn>
                <fn id="iahsp.TF.1.5">
                  <label>5.&#x000a0;</label>
                  <p>Somatosensory evoked potentials</p>
                </fn>
                <fn id="iahsp.TF.1.6">
                  <label>6.&#x000a0;</label>
                  <p>Electromyography</p>
                </fn>
                <fn id="iahsp.TF.1.7">
                  <label>7.&#x000a0;</label>
                  <p>Nerve conduction velocities</p>
                </fn>
                <fn id="iahsp.TF.1.8">
                  <label>8.&#x000a0;</label>
                  <p>Visual evoked potentials</p>
                </fn>
                <fn id="iahsp.TF.1.9">
                  <label>9.&#x000a0;</label>
                  <p>Brain stem auditory evoked potentials</p>
                </fn>
                <fn id="iahsp.TF.1.10">
                  <label>10.&#x000a0;</label>
                  <p>Transcranial magnetic stimulation</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
          <sec id="iahsp.Neuroimaging_Findings">
            <title>Neuroimaging Findings</title>
            <p><bold>IAHSP.</bold> Magnetic resonance imaging (MRI) is normal in children.</p>
            <p>Older individuals have:</p>
            <list list-type="bullet">
              <list-item>
                <p>Brain cortical atrophy predominant in the motor areas</p>
              </list-item>
              <list-item>
                <p>T<sub>2</sub>-weighted bilateral punctate hyperintense signals in the corticospinal pathways of the posterior arms of the internal capsule and brain stem.</p>
              </list-item>
            </list>
            <p>In addition, it is common to find T<sub>2</sub>- or FLAIR-weighted hyperintensities of periventricular areas and aspects of spinal cervical atrophy that are often seen in other <related-object link-type="booklink" source-id="gene" document-id="hsp" document-type="chapter">hereditary spastic paraplegias</related-object> (HSPs).</p>
            <p><bold>JPLS.</bold> CT and MRI scans of brain and spinal cord are normal.</p>
            <p><bold>JALS.</bold> MRI studies of brain and spinal cord are normal [<xref ref-type="bibr" rid="iahsp.REF.kress.2005.800">Kress et al 2005</xref>, <xref ref-type="bibr" rid="iahsp.REF.shirakawa.2009.2124">Shirakawa et al 2009</xref>].</p>
          </sec>
        </sec>
        <sec id="iahsp.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of an <italic toggle="yes">ALS2</italic>-related disorder <bold>is established</bold> in a proband with the identification of biallelic pathogenic variants in <italic toggle="yes">ALS2</italic> on molecular genetic testing (see <xref ref-type="table" rid="iahsp.T.electrophysiologic_studies_in_al">Table 1</xref>).</p>
          <p>Molecular testing approaches can include <bold>single-gene testing</bold> and use of a <bold>multi-gene panel.</bold></p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">ALS2</italic> is performed first followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found. Note that while no <italic toggle="yes">ALS2</italic> exon or whole-gene deletions/duplications have been reported to date, loss of <italic toggle="yes">ALS2</italic> function due to these mechanisms would be expected to cause disease; thus, use of gene-targeted deletion/duplication analysis in this instance is a reasonable option.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">ALS2</italic> and other genes of interest (see <xref ref-type="sec" rid="iahsp.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the causative gene at the most reasonable cost.</p>
            </list-item>
          </list>
          <table-wrap id="iahsp.T.molecular_genetic_testing_used_i" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p>Molecular Genetic Testing Used in <italic toggle="yes">ALS2</italic>-Related Disorders</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_iahsp.T.molecular_genetic_testing_used_i_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_iahsp.T.molecular_genetic_testing_used_i_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_iahsp.T.molecular_genetic_testing_used_i_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_iahsp.T.molecular_genetic_testing_used_i_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">ALS2</italic>
                  </td>
                  <td headers="hd_h_iahsp.T.molecular_genetic_testing_used_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_iahsp.T.molecular_genetic_testing_used_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">All sequence variants reported to date</td>
                </tr>
                <tr>
                  <td headers="hd_h_iahsp.T.molecular_genetic_testing_used_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_iahsp.T.molecular_genetic_testing_used_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">None reported&#x000a0;<sup>5</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="iahsp.TF.2.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="iahsp" object-id="iashp.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="iahsp.TF.2.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="iahsp.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="iahsp.TF.2.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="iahsp.TF.2.4">
                <label>4. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used can include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="iahsp.TF.2.5">
                <label>5. </label>
                <p>No data on detection rate of gene-targeted deletion/duplication analysis are available; however, loss of <italic toggle="yes">ALS2</italic> function due to a large deletion or duplication is expected to cause disease.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="iahsp.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="iahsp.Clinical_Description">
          <title>Clinical Description</title>
          <p>Pathogenic variants in <italic toggle="yes">ALS2</italic> are responsible for a retrograde degeneration of the upper motor neurons of the pyramidal tracts, leading to a clinical continuum from infantile ascending hereditary spastic paraplegia to juvenile forms without lower motor neuron involvement (juvenile primary lateral sclerosis) or with lower motor neuron involvement (autosomal recessive juvenile amyotrophic lateral sclerosis).</p>
          <p><bold>Infantile ascending hereditary spastic paraplegia (IAHSP).</bold> Spastic paraplegia begins during the first two years of life and extends to upper limbs within the next few years. Manifestations of the disease may start as early as the first year of life. During the first decade of life, the disease progresses to tetraplegia, anarthria, dysphagia, and slow eye movements.</p>
          <p>Feeding difficulties, especially in swallowing liquids, may manifest in the second decade; however, those few individuals with long-term follow up who have reached their 30s have neither experienced recurrent bronchopneumonia nor required feeding gastrostomy. Some individuals are reported to require feeding by gastrostomy tube and to lose bladder and sphincter functions in the advanced state [<xref ref-type="bibr" rid="iahsp.REF.verschuurenbemelmans.2008.1407">Verschuuren-Bemelmans et al 2008</xref>].</p>
          <p>Overall, IAHSP is compatible with long survival. Cognitive function is preserved.</p>
          <p><bold>Juvenile primary lateral sclerosis (JPLS).</bold> Examination reveals upper motor neuron findings of pseudobulbar palsy and spastic quadriplegia without dementia or cerebellar, extrapyramidal, or sensory signs. In addition, affected individuals exhibit a diffuse conjugate saccadic gaze paresis, especially severe on downgaze. Some of these children are never able to walk independently, while others are delayed in walking and then lose the ability to walk independently by the first decade of life. Speech deterioration starts between ages two and ten years. No cognitive deterioration is reported. Survival is variable.</p>
          <p>Intrafamilial variability can be considerable: in one family with two affected sibs with onset in early childhood, one began using a wheelchair at age two years (and was alive at age 42 years); the other began using a wheelchair at age 50 years (and was alive at age 55 years) [<xref ref-type="bibr" rid="iahsp.REF.mintchev.2009.28">Mintchev et al 2009</xref>].</p>
          <p><bold>Autosomal recessive juvenile amyotrophic lateral sclerosis (JALS or ALS2)</bold> [<xref ref-type="bibr" rid="iahsp.REF.ben_hamida.1990.347">Ben Hamida et al 1990</xref>, <xref ref-type="bibr" rid="iahsp.REF.hentati.1994.425">Hentati et al 1994</xref>]. Onset is between ages three and 20 years. All affected show a spastic pseudobulbar syndrome together with spastic paraplegia. Peroneal muscular atrophy is observed in some, but not all, individuals. Atrophy or fasciculation of the tongue does not occur. At the time of the description of clinical symptoms, three individuals from one family were bedridden by age 12, 20, and 50 years, but another remained ambulatory until age 50 years.</p>
          <p><bold>Other.</bold> Two families with homozygous <italic toggle="yes">ALS2</italic> pathogenic variants have been reported to demonstrate generalized dystonia and cerebellar signs [<xref ref-type="bibr" rid="iahsp.REF.sheerin.2014.1065">Sheerin et al 2014</xref>].</p>
        </sec>
        <sec id="iahsp.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Both IAHSP and JPLS have been associated with truncating <italic toggle="yes">ALS2</italic> variants. Generally, the IAHSP and JPLS phenotypes are uniform within families (based on data regarding individuals from 9 families).</p>
        </sec>
        <sec id="iahsp.Nomenclature">
          <title>Nomenclature</title>
          <p>See <related-object link-type="booklink" source-id="gene" document-id="als-overview" document-type="chapter">Amyotrophic Lateral Sclerosis Overview</related-object>.</p>
        </sec>
        <sec id="iahsp.Prevalence">
          <title>Prevalence</title>
          <p>No data on prevalence are available, but <italic toggle="yes">ALS2</italic>-related disorders are probably currently underdiagnosed.</p>
          <p><italic toggle="yes">ALS2</italic>-related disorders have been described in individuals from a variety of ethnic backgrounds.</p>
        </sec>
      </sec>
      <sec id="iahsp.Genetically_Related_Allelic_Disord">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">ALS2</italic>.</p>
      </sec>
      <sec id="iahsp.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <sec id="iahsp.Hereditary_Spastic_Paraplegia_HSP">
          <title>Hereditary Spastic Paraplegia (HSP)</title>
          <p>For a detailed discussion of HSP and the differential diagnosis of HSP, see the <related-object link-type="booklink" source-id="gene" document-id="hsp" document-type="chapter">Hereditary Spastic Paraplegia Overview</related-object>.</p>
          <p>The hereditary spastic paraplegias are clinically and genetically heterogeneous disorders characterized by insidiously progressive lower extremity weakness and spasticity. Hereditary spastic paraplegia may be transmitted in an autosomal dominant, autosomal recessive, X-linked, or maternally inherited (mitochondrial) manner.</p>
          <p>Children with autosomal dominant HSP and with congenital onset of spasticity (<related-object link-type="booklink" source-id="gene" document-id="spg4" document-type="chapter">SPG4</related-object>, caused by pathogenic variants in <italic toggle="yes">SPAST</italic> encoding spastin and <related-object link-type="booklink" source-id="gene" document-id="spg3a" document-type="chapter">SPG3A</related-object>, caused by pathogenic variants in <italic toggle="yes">ATL1</italic> encoding atlastin) have a non-progressive or very slowly progressive course, whereas in the most common presentation of HSP with onset of spasticity and weakness in adulthood, the course is clearly progressive.</p>
          <p><bold>IAHSP without <italic toggle="yes">ALS2</italic> pathogenic variants.</bold> Genetic heterogeneity has been demonstrated by <xref ref-type="bibr" rid="iahsp.REF.lesca.2003.674">Lesca et al [2003]</xref> by the fact of only four of 11 families with IAHSP have <italic toggle="yes">ALS2</italic> pathogenic variants. No other genes/loci causing this phenotype have been identified.</p>
          <p><bold>ARHSP.</bold> In general, in autosomal recessive hereditary spastic paraplegia (ARHSP) with onset during childhood, the progression is less severe and spasticity predominates over weakness. Pseudobulbar involvement in <italic toggle="yes">ALS2</italic>-related disorders clearly delineates it from all the other genetic forms of spastic paraparesis. In contrast, in ARHSP, muscle weakness predominates over spasticity, onset is clearly apparent during the first decade, and involvement of upper limbs and bulbar function is invariable. The role of <italic toggle="yes">ALS2</italic> pathogenic variants in ARHSP has not yet been investigated.</p>
          <p>Normal brain white matter on MRI rules out the diagnosis of leukodystrophy (see <related-object link-type="booklink" source-id="gene" document-id="leukodys-ov" document-type="chapter">Leukodystrophy Overview</related-object>).</p>
          <p>Metabolic investigations rule out other metabolic causes of progressive ARHSP (very long chain fatty acids [see <related-object link-type="booklink" source-id="gene" document-id="x-ald" document-type="chapter">X-Linked Adrenoleukodystrophy</related-object>], <related-object link-type="booklink" source-id="gene" document-id="mld" document-type="chapter">arylsulfatase A deficiency</related-object>, mitochondrial dysfunction [see <related-object link-type="booklink" source-id="gene" document-id="mt-overview" document-type="chapter">Mitochondrial Disorders Overview</related-object>]); however, decline in behavior or cognitive function is frequently observed in these conditions.</p>
          <p><bold>Primary lateral sclerosis (PLS)</bold> is defined as the presence of slowly progressive, uncomplicated signs of upper motor neuron disease in persons in whom all other known causes of spasticity have been eliminated. PLS has been described in adults with an isolated degenerative process of the upper motor neurons, with sporadic occurrence [<xref ref-type="bibr" rid="iahsp.REF.pringle.1992.495">Pringle et al 1992</xref>]. No <italic toggle="yes">ALS2</italic> pathogenic variants were identified in a study of 51 Dutch persons with adult-onset PLS [<xref ref-type="bibr" rid="iahsp.REF.brugman.2007.702">Brugman et al 2007</xref>].</p>
          <p><xref ref-type="bibr" rid="iahsp.REF.alsaif.2012.510">Al-Saif et al [2012]</xref> described a consanguineous family from Saudi Arabia having four sibs with infantile-onset PLS with severe progression requiring wheelchair by age 12 and associated with a homozygous splice junction pathogenic variant (c.499-1G&#x0003e;T) in <italic toggle="yes">ERLIN2</italic> [OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/611225">611225</ext-link>].</p>
        </sec>
        <sec id="iahsp.Amyotrophic_Lateral_Sclerosis_ALS">
          <title>Amyotrophic Lateral Sclerosis (ALS)</title>
          <p>For a detailed discussion of ALS and the differential diagnosis of ALS, see <related-object link-type="booklink" source-id="gene" document-id="als-overview" document-type="chapter">Amyotrophic Lateral Sclerosis Overview</related-object>.</p>
          <p>ALS is a progressive neurodegenerative disease involving both the upper motor neurons (UMN) and lower motor neurons (LMN). LMN signs include weakness, muscle wasting, muscle cramps, fasciculations, and eventually hyporeflexia. UMN signs include hyperreflexia, extensor plantar response, increased muscle tone, and weakness in a topographic representation. Approximately 25 genes are currently thought to be associated with ALS; of these, <italic toggle="yes">ALS2</italic>, <italic toggle="yes">SETX</italic> (ALS4), and <italic toggle="yes">SIGMAR1</italic> (ALS16) are associated with juvenile onset [<xref ref-type="bibr" rid="iahsp.REF.marangi.2015.75">Marangi &#x00026; Traynor 2015</xref>].</p>
          <p><bold>ALS4</bold> is an autosomal dominant form of ALS, with signs and symptoms of both upper and lower motor neuron involvement and onset before age 25 years. This has also been described as a distal hereditary motor neuropathy with pyramidal signs. Individuals with ALS4 usually have onset before age 25 years, a slow rate of progression, and a normal life span [<xref ref-type="bibr" rid="iahsp.REF.chen.2004.1128">Chen et al 2004</xref>]. ALS4 is caused by mutation of <italic toggle="yes">SETX</italic>.</p>
          <p><bold>ALS5</bold> (also known as type 1 autosomal recessive ALS) very closely resembles typical ALS of any age of onset and is the most prevalent form of autosomal recessive ALS, having been identified in several ethnic groups (North African, South Asian, and European). This form of recessive ALS was mapped to 15q by <xref ref-type="bibr" rid="iahsp.REF.hentati.1998.55">Hentati et al [1998]</xref>.</p>
          <p><bold>ALS16.</bold>
<xref ref-type="bibr" rid="iahsp.REF.alsaif.2011.913">Al-Saif et al [2011]</xref> reported a consanguineous family from Saudi Arabia with juvenile ALS (onset age 1-2 years, slowly progressing to use of a wheelchair by age 20 years) with a homozygous pathogenic missense variant (c.304G&#x0003e;C, p.Glu102Gln) in <italic toggle="yes">SIGMAR1</italic> [OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/614373">614373</ext-link>].</p>
        </sec>
      </sec>
      <sec id="iahsp.Management">
        <title>Management</title>
        <sec id="iahsp.Evaluations_Following_Initial_Diag">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with an <italic toggle="yes">ALS2</italic>-related disorder, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Family history</p>
            </list-item>
            <list-item>
              <p>Neurologic examination, including assessment of eye movements, speech, fine motor and gross motor function, swallowing</p>
            </list-item>
            <list-item>
              <p>Detailed dietary and feeding assessment as needed</p>
            </list-item>
            <list-item>
              <p>Orthopedic and rehabilitation assessment as needed</p>
            </list-item>
            <list-item>
              <p>Consultation with a medical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="iahsp.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>The following are appropriate:</p>
          <list list-type="bullet">
            <list-item>
              <p>Physical and occupational therapy to promote mobility and independence</p>
            </list-item>
            <list-item>
              <p>Aids for mobility and limb function</p>
            </list-item>
            <list-item>
              <p>Use of computer technologies and devices adapted to facilitate writing and voice communication</p>
            </list-item>
          </list>
        </sec>
        <sec id="iahsp.Surveillance">
          <title>Surveillance</title>
          <p>Routine monitoring:</p>
          <list list-type="bullet">
            <list-item>
              <p>For feeding difficulties and assessment of diet to assure that the risk of aspiration is reduced</p>
            </list-item>
            <list-item>
              <p>For early detection and treatment of hip dislocation and/or spine deformities</p>
            </list-item>
          </list>
        </sec>
        <sec id="iahsp.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="iahsp.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="iahsp.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="iahsp.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="iahsp.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">ALS2</italic>-related disorders are inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="iahsp.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">ALS2</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Individuals with <italic toggle="yes">ALS2</italic>-related disorders have marked motor disability and have not been known to reproduce.</p>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier of an <italic toggle="yes">ALS2</italic> pathogenic variant.</p>
        </sec>
        <sec id="iahsp.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">ALS2</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="iahsp.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="iahsp.Prenatal_Testing_and_Preimplantati">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">ALS2</italic> pathogenic variants have been identified in an affected family member, prenatal testing or preimplantation genetic diagnosis for a pregnancy at increased risk for an <italic toggle="yes">ALS2</italic>-related disorder may be an option that a couple may wish to consider.</p>
        </sec>
      </sec>
      <sec id="iahsp.Resources">
        <title>Resources</title>
      </sec>
      <sec id="iahsp.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold> The longer transcript variant of <italic toggle="yes">ALS2</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_020919.3">NM_020919.3</ext-link>) comprises 34 exons in a genomic region of 83 kb. Alternative splicing gives rise to a 184-kd full-length form of 1,657 amino acids and a smaller, alternatively spliced transcript of 396 amino acids (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_001135745.1">NM_001135745.1</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_001129217.1">NP_001129217.1</ext-link>). For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="iahsp" object-id="iahsp.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic allelic variants.</bold> Nearly 50 pathogenic variants, many homozygous, have been reported in individuals with <italic toggle="yes">ALS2</italic>-related disorders. These variants include frameshift, nonsense, splice site, and missense variants. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="iahsp-Table3.pdf" content-type="local-data">Table 3</inline-supplementary-material> (pdf) and <xref ref-type="fig" rid="iahsp.F1">Figure 1</xref>.</p>
        <p><bold>Normal gene product.</bold> Sequence comparisons suggest that <italic toggle="yes">ALS2</italic> encodes the protein alsin which contains three guanine nucleotide exchange factor (GEF) domains: RCC1(regulator of chromatin condensation)-like domain (RLD); the Dbl homology and pleckstrin homology (DH/PH); and the vacuolar protein sorting 9 (VPS9) (see <xref ref-type="fig" rid="iahsp.F1">Figure 1</xref>). GEF activates one or more small GTPases, facilitating the releasing of GDP and exchange for GTP. Alsin acts as a GEF for Rab5, a GTPase implicated in endosomal trafficking [<xref ref-type="bibr" rid="iahsp.REF.otomo.2003.1671">Otomo et al 2003</xref>, <xref ref-type="bibr" rid="iahsp.REF.hadano.2007.74">Hadano et al 2007</xref>]. Alsin acts on Rac1, a G protein involved in actin cytoskeleton remodeling [<xref ref-type="bibr" rid="iahsp.REF.topp.2004.24612">Topp et al 2004</xref>, <xref ref-type="bibr" rid="iahsp.REF.kanekura.2005.4532">Kanekura et al 2005</xref>], and recruits active Rac1 to membrane ruffles facilitating Rac1-activated endocytosis [<xref ref-type="bibr" rid="iahsp.REF.kunita.2007.16599">Kunita et al 2007</xref>].</p>
        <p>Endogenous alsin is enriched in nerve tissue where it is peripherally bound to the cytoplasmic face of endosomal membranes [<xref ref-type="bibr" rid="iahsp.REF.otomo.2003.1671">Otomo et al 2003</xref>, <xref ref-type="bibr" rid="iahsp.REF.yamanaka.2003.16041">Yamanaka et al 2003</xref>, <xref ref-type="bibr" rid="iahsp.REF.kunita.2004.38626">Kunita et al 2004</xref>, <xref ref-type="bibr" rid="iahsp.REF.topp.2004.24612">Topp et al 2004</xref>]. Alsin is also present in membrane ruffles and lamellipodia [<xref ref-type="bibr" rid="iahsp.REF.topp.2004.24612">Topp et al 2004</xref>], suggesting that alsin is involved in membrane transport events, potentially linking endocytic processes and actin cytoskeleton remodeling.</p>
        <p>The function of alsin in the nervous system has been tested in alsin-deficient mice and the primary neurons from them. Neuropathologic analysis exhibited mild axonal degeneration in the dorsolateral [<xref ref-type="bibr" rid="iahsp.REF.yamanaka.2006.95">Yamanaka et al 2006</xref>] or distal corticospinal tracts [<xref ref-type="bibr" rid="iahsp.REF.deng.2007.2911">Deng et al 2007</xref>, <xref ref-type="bibr" rid="iahsp.REF.groslouis.2008.2691">Gros-Louis et al 2008</xref>], or progressive loss of cerebellar Purkinje cells with decreased number of motor axons from lumbar spinal cord [<xref ref-type="bibr" rid="iahsp.REF.hadano.2006.233">Hadano et al 2006</xref>]. Modest behavioral abnormalities observed in alsin-deficient mice included motor slowness and/or decreased motor coordination measured by rotarod performance [<xref ref-type="bibr" rid="iahsp.REF.cai.2005.7567">Cai et al 2005</xref>, <xref ref-type="bibr" rid="iahsp.REF.deng.2007.2911">Deng et al 2007</xref>, <xref ref-type="bibr" rid="iahsp.REF.yamanaka.2006.95">Yamanaka et al 2006</xref>]. Alsin-deficient mice have normal life span and a far milder phenotype than that observed in humans with <italic toggle="yes">ALS2</italic> pathogenic variants.</p>
        <p><bold>Abnormal gene product.</bold> Mutated alsin and a naturally truncated alsin isoform are rapidly degraded when expressed in cultured human cells, including lymphocytes and fibroblasts derived from individuals with <italic toggle="yes">ALS2</italic> pathogenic variants. Thus, pathogenic variants in <italic toggle="yes">ALS2</italic> linked to early-onset motor neuron disease uniformly produce loss of activity through decreased protein stability of this endosomal GEF [<xref ref-type="bibr" rid="iahsp.REF.yamanaka.2003.16041">Yamanaka et al 2003</xref>].</p>
        <p>Some reported <italic toggle="yes">ALS2</italic> pathogenic variants causing motor neuron diseases are reported to be associated with a loss of protein stability [<xref ref-type="bibr" rid="iahsp.REF.yamanaka.2003.16041">Yamanaka et al 2003</xref>], which leads to reduction or loss of all three potential GEF domains. A current research focus is the role of alsin as a Rab5-GEF and its involvement in endosomal dynamics. It is premature to discount roles for the other GEF domains as well as corresponding GTPases in understanding the role of alsin in the death of upper motor neurons beginning in early postnatal life.</p>
      </sec>
      <sec id="iahsp.References">
        <title>References</title>
        <sec id="iahsp.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="iahsp.Literature_Cited.reflist0">
            <ref id="iahsp.REF.alsaif.2011.913">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Al-Saif</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Mohanna</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bohlega</surname>
                    <given-names>S.</given-names>
                  </name>
                </person-group>
                <article-title>A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis.</article-title>
                <source>Ann Neurol.</source>
                <year>2011</year>
                <volume>70</volume>
                <fpage>913</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21842496</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.alsaif.2012.510">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Al-Saif</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bohlega</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Mohanna</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Loss of ERLIN2 function leads to juvenile primary lateral sclerosis.</article-title>
                <source>Ann Neurol.</source>
                <year>2012</year>
                <volume>72</volume>
                <fpage>510</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">23109145</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.ben_hamida.1990.347">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ben Hamida</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hentati</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben Hamida</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>1990</year>
                <article-title>Hereditary motor system diseases (chronic juvenile amyotrophic lateral sclerosis). Conditions combining a bilateral pyramidal syndrome with limb and bulbar amyotrophy.</article-title>
                <source>Brain</source>
                <volume>113</volume>
                <fpage>347</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">2328408</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.brugman.2007.702">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brugman</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eymard-Pierre</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Berg</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wokke</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gauthier-Barichard</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boespflug-Tanguy</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Adult-onset primary lateral sclerosis is not associated with mutations in the ALS2 gene.</article-title>
                <source>Neurology</source>
                <volume>69</volume>
                <fpage>702</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">17698795</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.cai.2005.7567">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cai</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xie</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laird</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lai</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wen</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiang</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shim</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farah</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoke</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Price</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>PC</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Loss of ALS2 function is insufficient to trigger motor neuron degeneration in knock-out mice but predisposes neurons to oxidative stress.</article-title>
                <source>J Neurosci.</source>
                <volume>25</volume>
                <fpage>7567</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">16107644</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.chen.2004.1128">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>Y-Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huynh</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blair</surname>
                    <given-names>IP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puls</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Irobi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dirick</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kennerson</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rabin</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicholson</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Auer-Grumbach</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wagner</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffin</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischbeck</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmerman</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cornblath</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chance</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4).</article-title>
                <source>Am J Hum Genet</source>
                <volume>74</volume>
                <fpage>1128</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">15106121</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.deng.2007.2911">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Deng</surname>
                    <given-names>HX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhai</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fu</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorrie</surname>
                    <given-names>GH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dal Canto</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mugnaini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siddique</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Distal axonopathy in an alsin-deficient mouse model.</article-title>
                <source>Hum Mol Genet.</source>
                <volume>16</volume>
                <fpage>2911</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">17855450</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.gascon.1995.313">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gascon</surname>
                    <given-names>GG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chavis</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaghmour</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stigsby</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shums</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozand</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siddique</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Familial childhood primary lateral sclerosis with associated gaze paresis.</article-title>
                <source>Neuropediatrics</source>
                <volume>26</volume>
                <fpage>313</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">8719747</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.groslouis.2008.2691">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gros-Louis</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kriz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kabashi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDearmid</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Millecamps</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urushitani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dion</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drapeau</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Julien</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Als2 mRNA splicing variants detected in KO mice rescue severe motor dysfunction phenotype in Als2 knock-down zebrafish.</article-title>
                <source>Hum Mol Genet</source>
                <volume>17</volume>
                <fpage>2691</fpage>
                <lpage>702</lpage>
                <pub-id pub-id-type="pmid">18558633</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.hadano.2006.233">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hadano</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benn</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kakuta</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otomo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sudo</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kunita</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki-Utsunomiya</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizumura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shefner</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iwakura</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>RH</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/alsin exhibit age-dependent neurological deficits and altered endosome trafficking.</article-title>
                <source>Hum Mol Genet</source>
                <volume>15</volume>
                <fpage>233</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">16321985</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.hadano.2007.74">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hadano</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kunita</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otomo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki-Utsunomiya</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Molecular and cellular function of ALS2/alsin: implication of membrane dynamics in neuronal development and degeneration.</article-title>
                <source>Neurochem Int</source>
                <volume>51</volume>
                <fpage>74</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">17566607</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.hentati.1994.425">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hentati</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bejaoui</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pericak-Vance</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hentati</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speer</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hung</surname>
                    <given-names>WY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Figlewicz</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haines</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rimmler</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben Hamida</surname>
                    <given-names>C</given-names>
                  </name>
                  <etal/>
                </person-group>
                <year>1994</year>
                <article-title>Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35.</article-title>
                <source>Nat Genet.</source>
                <volume>7</volume>
                <fpage>425</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">7920663</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.hentati.1998.55">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hentati</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ouahchi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pericak-Vance</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nijhawan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahmad</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rimmler</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hung</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlotter</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahmed</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben Hamida</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hentati</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siddique</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers.</article-title>
                <source>Neurogenetics</source>
                <volume>2</volume>
                <fpage>55</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">9933301</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.kanekura.2005.4532">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kanekura</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hashimoto</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kita</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sasabe</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aiso</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishimoto</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuoka</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>A Rac1/phosphatidylinositol 3-kinase/Akt3 anti-apoptotic pathway, triggered by AlsinLF, the product of the ALS2 gene, antagonizes Cu/Zn-superoxide dismutase (SOD1) mutant-induced motoneuronal cell death.</article-title>
                <source>J Biol Chem</source>
                <volume>280</volume>
                <fpage>4532</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">15579468</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.kress.2005.800">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kress</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000fc;hnlein</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winter</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ludolph</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kassubek</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sperfeld</surname>
                    <given-names>AD</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Novel mutation in the ALS2 gene in juvenile amyotrophic lateral sclerosis.</article-title>
                <source>Ann Neurol.</source>
                <volume>58</volume>
                <fpage>800</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">16240357</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.kunita.2004.38626">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kunita</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otomo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizumura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Showguchi-Miyata</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yanagisawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadano</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Homo-oligomerization of ALS2 through its unique carboxyl-terminal regions is essential for the ALS2-associated Rab5 guanine nucleotide exchange activity and its regulatory function on endosome trafficking.</article-title>
                <source>J Biol Chem</source>
                <volume>279</volume>
                <fpage>38626</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">15247254</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.kunita.2007.16599">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kunita</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otomo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizumura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki-Utsunomiya</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadano</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>The Rab5 activator ALS2/alsin acts as a novel Rac1 effector through Rac1-activated endocytosis.</article-title>
                <source>J Biol Chem</source>
                <volume>282</volume>
                <fpage>16599</fpage>
                <lpage>611</lpage>
                <pub-id pub-id-type="pmid">17409386</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.lesca.2003.674">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lesca</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eymard-Pierre</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santorelli</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cusmai</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Capua</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valente</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Attia-Sobol</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plauchu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leuzzi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ponzone</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boespflug-Tanguy</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Infantile ascending hereditary spastic paralysis (IAHSP): clinical features in 11 families.</article-title>
                <source>Neurology</source>
                <volume>60</volume>
                <fpage>674</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">12601111</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.marangi.2015.75">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marangi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Traynor</surname>
                    <given-names>BJ</given-names>
                  </name>
                </person-group>
                <article-title>Genetic causes of amyotrophic lateral sclerosis: New genetic analysis methodologies entailing new opportunities and challenges.</article-title>
                <source>Brain Res.</source>
                <year>2015</year>
                <volume>1607</volume>
                <fpage>75</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">25316630</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.mintchev.2009.28">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mintchev</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zamba-Papanicolaou</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleopa</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christodoulou</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>A novel ALS2 splice-site mutation in a Cypriot juvenile-onset primary lateral sclerosis family.</article-title>
                <source>Neurology</source>
                <volume>72</volume>
                <fpage>28</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">19122027</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.otomo.2003.1671">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Otomo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadano</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okada</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizumura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kunita</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishijima</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Showguchi-Miyata</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yanagisawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohiki</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suga</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasuda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osuga</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishimoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Narumiya</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>ALS2, a novel guanine nucleotide exchange factor for the small GTPase Rab5, is implicated in endosomal dynamics.</article-title>
                <source>Hum Mol Genet</source>
                <volume>12</volume>
                <fpage>1671</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">12837691</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.pringle.1992.495">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pringle</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hudson</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munoz</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kiernan</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>WF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ebers</surname>
                    <given-names>GC</given-names>
                  </name>
                </person-group>
                <year>1992</year>
                <article-title>Primary lateral sclerosis. Clinical features, neuropathology and diagnostic criteria.</article-title>
                <source>Brain</source>
                <volume>115</volume>
                <fpage>495</fpage>
                <lpage>520</lpage>
                <pub-id pub-id-type="pmid">1606479</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.sheerin.2014.1065">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sheerin</surname>
                    <given-names>U-M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carr</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deuschl</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopfner</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stamelou</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>NW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhatia</surname>
                    <given-names>KP</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>ALS2 mutations. Juvenile amyotrophic lateral sclerosis and generalized dystonia.</article-title>
                <source>Neurology</source>
                <volume>82</volume>
                <fpage>1065</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">24562058</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.shirakawa.2009.2124">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shirakawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kono</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uchiyama</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohashi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Novel compound heterozygous ALS2 mutations cause juvenile amyotrophic lateral sclerosis in Japan.</article-title>
                <source>Neurology.</source>
                <volume>73</volume>
                <fpage>2124</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">20018642</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.topp.2004.24612">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Topp</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gray</surname>
                    <given-names>NW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerard</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horazdovsky</surname>
                    <given-names>BF</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Alsin is a Rab5 and Rac1 guanine nucleotide exchange factor.</article-title>
                <source>J Biol Chem</source>
                <volume>279</volume>
                <fpage>24612</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">15033976</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.verschuurenbemelmans.2008.1407">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Verschuuren-Bemelmans</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winter</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sival</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elting</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brouwer</surname>
                    <given-names>OF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller</surname>
                    <given-names>U</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Novel homozygous ALS2 nonsense mutation (p.Gln715X) in sibs with infantile-onset ascending spastic paralysis: the first cases from northwestern Europe</article-title>
                <source>Eur J Hum Genet.</source>
                <volume>16</volume>
                <fpage>1407</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">18523452</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.yamanaka.2006.95">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yamanaka</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McAlonis-Downes</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chun</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cleveland</surname>
                    <given-names>DW</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Progressive spinal axonal degeneration and slowness in ALS2-deficient mice.</article-title>
                <source>Ann Neurol</source>
                <volume>60</volume>
                <fpage>95</fpage>
                <lpage>104</lpage>
                <pub-id pub-id-type="pmid">16802286</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.yamanaka.2003.16041">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yamanaka</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vande Velde</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eymard-Pierre</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boespflug-Tanguy</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cleveland</surname>
                    <given-names>DW</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Unstable mutants in the peripheral endosomal membrane component ALS2 cause early-onset motor neuron disease.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <volume>100</volume>
                <fpage>16041</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">14668431</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.yang.2001.160">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hentati</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deng</surname>
                    <given-names>HX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dabbagh</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sasaki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hung</surname>
                    <given-names>WY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ouahchi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azim</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cole</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gascon</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yagmour</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben-Hamida</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pericak-Vance</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hentati</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siddique</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis.</article-title>
                <source>Nat Genet</source>
                <volume>29</volume>
                <fpage>160</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">11586297</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="iahsp.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="iahsp.Suggested_Reading.reflist0">
            <ref id="iahsp.REF.dion.2009.769">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dion</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daoud</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Genetics of motor neuron disorders: new insights into pathogenic mechanisms.</article-title>
                <source>Nat Rev Genet</source>
                <volume>10</volume>
                <fpage>769</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">19823194</pub-id>
              </element-citation>
            </ref>
            <ref id="iahsp.REF.singer.2007.291">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Singer</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Statland</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolfe</surname>
                    <given-names>GI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barohn</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Primary lateral sclerosis.</article-title>
                <source>Muscle Nerve.</source>
                <volume>35</volume>
                <fpage>291</fpage>
                <lpage>302</lpage>
                <pub-id pub-id-type="pmid">17212349</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="iahsp.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="iahsp.Author_History">
          <title>Author History</title>
          <p>Enrico S Bertini, MD; Ospedale Bambino Gesu, Rome (2005-2016)Odile Boespflug-Tanguy, MD, PhD; Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale, Clermont-Ferrand (2005-2016)Don W Cleveland, PhD, University of California San Diego (2005-2016)Eleonore Eymard-Pierre, PhD; Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale, Clermont-Ferrand (2005-2016)Richard W Orrell, BSc, MD, FRCP (2016-present)Koji Yamanaka, MD, PhD; RIKEN Brain Science Institute, Wako (2005-2016)</p>
        </sec>
        <sec id="iahsp.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>28 January 2016 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>18 April 2013 (tb) Revision: information on mutations in <italic toggle="yes">ERLIN2</italic> and <italic toggle="yes">SIGMAR1</italic> added to <xref ref-type="sec" rid="iahsp.Differential_Diagnosis">Differential Diagnosis</xref></p>
            </list-item>
            <list-item>
              <p>10 February 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>21 October 2005 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>16 December 2004 (esb) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="iahsp.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Schematic representation of the Alsin protein domain structure with reported amino acid changes indicatedAlsin protein with RCC1 (regulator of chromatin condensation)-like domain (RLD), DH/PH (Dbl and pleckstrin homology), and VPS9 (vacuolar protein sorting 9) have the highest sequence similarity to guanine nucleotide exchange factors for the Ran, Rho, and Rab5 families of guanosine triphosphatases, respectively. MORN (<italic toggle="yes">m</italic>embrane <italic toggle="yes">o</italic>ccupation and <italic toggle="yes">r</italic>ecognition <italic toggle="yes">n</italic>exus) motifs are implicated in the binding of the plasma membrane. Numbers below the domains indicate the amino acid position of each domain along the protein sequence.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="iahsp-Image001" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
